Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-16

Clinical Trial Update: A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating two doses of GSK2402968 in Duchenne muscular dystrophy has completed, with results posted in October 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GSK2402968

Snippet

Sponsor: GlaxoSmithKline | Conditions: Muscular Dystrophies | Phase 2 | Status: COMPLETED | Results posted: 2017-10-16